Gonadal dysfunction in Morbidly Obese Adolescent Girls
Abstract
Objective To describe gonadal dysfunction and evaluate polycystic ovary syndrome (PCOS) and its association with metabolic syndrome (MeS) among girls in a morbidly obese adolescent population. Design In a cross-sectional study of 174 girls, height, weight, waist circumference, Tanner stage, reproductive hormones, carbohydrate and lipid markers, drug use and menstrual history were obtained at baseline. Exclusion criteria: menarchal age < 2 years, hormonal contraceptive or Metformin use, Tanner stage <4, incomplete data on PCOS or MeS classification. Setting University Medical Center outpatient clinic Patients 98 girls ages 13–19.6 years, Tanner 5, average BMI of 46.6 kg/m2, menarche at 11.4 years and average menarchal age of 5 years Interventions None Main Outcome Measures PCOS and MeS Results 98 girls were divided into 4 groups: PCOS by NIH criteria (PCOSN, n=24), irregular menses only (IM, n=25), elevated testosterone ≥ 55 ng/dL only (ET, n=6) and obese controls (OC, n=43). MeS by modified Cook criteria affected 32 girls or 33% overall, 6/24 PCOSN, 7/25 IM, 4/6 ET and 15/43 OC. PCOSN and its individual components were not associated with MeS after adjusting for BMI. Conclusion Unlike obese adults, PCOSN and its individual components were not associated with MeS in the untreated morbidly obese adolescent population.
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 43 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.